

Electronic Supplementary Information (SI) for
New Journal of Chemistry

**Synthesis of L-cysteine-based boron compounds and their
evaluation as proteasome inhibitors**

Priscila Milani^a, Marilene Demasi^{b#}, Leandro de Rezende^c, Antonia T. do Amaral^c
and Leandro H. Andrade ^{a*}

^a *Laboratório de Química Fina e Biocatálise, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, SP 05508-900, São Paulo, Brazil.*

^b *Laboratório de Bioquímica e Biofísica, Instituto Butantan, Av. Vital Brasil, 1500, SP 05503-900 001 - São Paulo, Brazil.*

^c *Laboratório de QSAR e Modelagem Molecular de Compostos Bioativos, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, SP 05508-900, São Paulo, Brazil.*

*Corresponding author: Leandro H. Andrade

email: leandroh@iq.usp.br

#Co-corresponding author: Marilene Demasi

Email: marimasi@butantan.gov.br




Figure S1: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **6**.




Figure S2: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **6**.

(*R*)-*tert*-butyl 3-(benzylthio)-1-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)propan-2-ylcarbamate **7a**:




Figure S3: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **7a**.




Figure S4: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **7a**.

(*R*)-*tert*-butyl 3-(benzylthio)-1-oxo-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)propan-2-ylcarbamate **7b**:




Figure S5: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **7b**.




Figure S6: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **7b**.

(*R*)-methyl 3-(benzylthio)-1-oxo-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)propan-2-ylcarbamate **7c**:




Figure S7: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **7c**.




Figure S8: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **7c**.

(*R*)-3-(benzylthio)-2-pivalamido-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamide **7d**:




Figure S9: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **7d**.




Figure S10: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **7d**.

(R)-tert-butyl-3-(methylthio)-1-oxo-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)propan-2-ylcarbamate **7e**:




Figure S11: ¹H NMR spectrum (200 MHz, CDCl₃) of compound **7e**.




Figure S12: ¹³C NMR spectrum (50 MHz, CDCl₃) of compound **7e**.

(R)-*N*-(3-(benzylthio)-1-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)propan-2-yl)pyrazine-2-carboxamide **7f**:




Figure S13: ^1H NMR spectrum (200 MHz, CDCl_3) of compound **7f**.




Figure S14: ^{13}C NMR spectrum (50 MHz, CDCl_3) of compound **7f**.

(R)-3-(3-(benzylthio)-2-(methoxycarbonylamino)propanamido)phenylboronic acid **7g**:




Figure S15: ¹H NMR spectrum (200 MHz, DMSO + D₂O) of compound **7g**.




Figure S16: ¹³C NMR spectrum (50 MHz, DMSO + D₂O) of compound **7g**.

(*R*)-*tert*-butyl 3-(benzylthio)-1-oxo-1-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propylamino)propan-2-yl)carbamate **8a**:




Figure S17: ^1H NMR spectrum (200 MHz, CDCl_3) of compound **8a**.




Figure S18: ^{13}C NMR spectrum (50 MHz, CDCl_3) of compound **8a**.

(R)-3-(3-(benzylthio)-2-((tert-butoxycarbonylamino)propanamido)propylboronic acid **8b**




Figure S19: ¹H NMR spectrum (200 MHz, DMSO + D₂O) of compound **8b**.




Figure S20: ¹³C NMR spectrum (200 MHz, DMSO + D₂O) of compound **8b**.

Determination of V_{\max} e K_m of proteasome 20S and complex proteasome 20S/inhibitor in different concentrations.

	V_{\max}	K_m
Control	3.764	0.078
Inhibitor 50 μM	2.198	0.109
Inhibitor 100 μM	2.108	0.140
Inhibitor 150 μM	2.038	0.171

- Evaluation of 4a-g as inhibitors of the β 5-site (chymotrypsin-like) of the mammalian 20S proteasome

